A preclinical study finds that a drug already FDA-approved for treating inflammatory conditions may help reduce both alcohol intake and pain sensitivity -- two issues that commonly co-occur with ...

Patents for denosumab expired in some European markets in June, although the drug is still protected in France, Italy, Spain, and the UK until 2025, when exclusivity also comes to an end in the US ...